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IMPORTANCE Early diagnosis of retinoblastoma, the most common intraocular cancer, can
save both a child’s life and vision. However, anecdotal evidence suggests that many children
across the world are diagnosed late. To our knowledge, the clinical presentation of
retinoblastoma has never been assessed on a global scale.
OBJECTIVES To report the retinoblastoma stage at diagnosis in patients across the world
during a single year, to investigate associations between clinical variables and national income
level, and to investigate risk factors for advanced disease at diagnosis.
DESIGN, SETTING, AND PARTICIPANTS A total of 278 retinoblastoma treatment centers were
recruited from June 2017 through December 2018 to participate in a cross-sectional analysis
of treatment-naive patients with retinoblastoma who were diagnosed in 2017.
MAIN OUTCOMES AND MEASURES Age at presentation, proportion of familial history of
retinoblastoma, and tumor stage and metastasis.
RESULTS The cohort included 4351 new patients from 153 countries; the median age at
diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4%) were
female. Most patients (n = 3685 [84.7%]) were from low- and middle-income countries
(LMICs). Globally, the most common indication for referral was leukocoria (n = 2638
[62.8%]), followed by strabismus (n = 429 [10.2%]) and proptosis (n = 309 [7.4%]). Patients
from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656
of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis.
Patients from low-income countries were diagnosed at a median age of 30.5 months, with
256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having
metastasis. Lower national income level was associated with older presentation age, higher
proportion of locally advanced disease and distant metastasis, and smaller proportion of
familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs
even after adjusting for age (odds ratio for low-income countries vs upper-middle–income
countries and HICs, 17.92 [95% CI, 12.94-24.80], and for lower-middle–income countries vs
upper-middle–income countries and HICs, 5.74 [95% CI, 4.30-7.68]).
CONCLUSIONS AND RELEVANCE This study is estimated to have included more than half of all
new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global
retinoblastoma burden lies, presented at an older age with more advanced disease and
demonstrated a smaller proportion of familial history of retinoblastoma, likely because many
do not reach a childbearing age. Given that retinoblastoma is curable, these data are
concerning and mandate intervention at national and international levels. Further studies are
needed to investigate factors, other than age at presentation, that may be associated with
advanced disease in LMICs.
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R etinoblastoma, the most common eye cancer of child-hood, is fatal if left untreated. Prognosis of patients withretinoblastoma in high-income countries (HICs) has im-
proved over the past 50 years, now reaching a near 100% dis-
ease-free survival rate.1-3 This is attributed to several factors, in-
cluding (1) creation of specialized referral centers, (2) decoding
of the genetic basis of the disease, (3) formation of screening pro-
grams, and (4) the introduction of chemotherapy.4 In HICs, reti-
noblastoma is a curable disease, and attention has now shifted
to eye salvage5,6 and improvement of quality of life.7 In low- and
middle-income countries (LMICs), where more than 80% of
global retinoblastoma cases arise, the prognosis is poor, and it
is assumed that this is because of delayed diagnosis and
treatment.8-10 Publications from LMICs are scarce, and many
countries do not report their retinoblastoma data.11 The stage
of retinoblastoma at the time of diagnosis in low-income,
middle-income, and high-income countries has not been sur-
veyed globally. This information is important for policy and
health care planning at national and international levels.
The objectives of this study are to (1) report the stage at
diagnosis in a large global sample of patients with retinoblas-
toma, (2) examine associations between clinical variables at
presentation and national-income level, and (3) investigate risk
factors for advanced disease at diagnosis.
Methods
This study originated from a consortium of retinoblastoma treat-
ment centers in 8 countries on 3 continents.12 From June 2017
throughDecember2018,allknownretinoblastomatreatmentcen-
ters across the world were contacted by means of personal com-
munications, presentations at scientific conferences, and linking
to professional societies in the fields of ophthalmology and on-
cology to form a global network. All centers involved in the diag-
nosis and treatment of patients with retinoblastoma, at least by
means of enucleation, were eligible to participate.
Study Design
This study adheres to the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) reporting
guidelines.13 It was a 1-year cross-sectional analysis that included
all treatment-naive patients with retinoblastoma who present-
ed to participating centers from January 1, 2017, to December 31,
2017, and who were treated or offered treatment for retinoblas-
toma. A predesigned form was used for data collection (eTable 1
in the Supplement). The data collected included country of resi-
dence, sex, first ocular symptom as noted by parents, age at first
indication of symptom, age and ocular indication at presentation
to the retinoblastoma treatment center, laterality, familial history
of retinoblastoma, staging according to the American Joint
Committee on Cancer Staging Manual, Eighth Edition14 and the
InternationalRetinoblastomaStagingSystem,15 andprimarytreat-
ment. Data on country of residence, sex, and laterality were mini-
mum criteria for patient enrollment. The staging classifications
were simplified to include only the major subcategories (eTable 2
in the Supplement). For the primary tumor site (cT), the eye with
the more advanced disease was used for analysis. Completed
forms were electronically uploaded onto a secure server, after
whichadataqualityassuranceprocesswasperformed(eMethods
in the Supplement).
The study was approved by the institutional review board
at the London School of Hygiene & Tropical Medicine, which
granted a waiver of patient informed consent. Participating cen-
ters applied for and received ethics clearance in their coun-
tries according to local institutional guidelines.
Statistical Analysis
All analyses were performed using R software, version 3.5.2
(R Foundation for Statistical Computing), and IBM SPSS Statis-
tics, version 25.0 (IBM Corp). The crude birth rate, country popu-
lation size, and country classification by national income level
were obtained from the 2017 World Population Prospects.16 The
predicted number of new patients with retinoblastoma per coun-
try was calculated as follows: [country population × crude birth
rate/1000/17 000], and predicted number per national income
level was the sum result of all countries at the same level.
Unless otherwise indicated, summary statistics are pre-
sented as median and interquartile range (25%-75%). The t test
was used to compare means of normally distributed continu-
ous variables, Fisher exact and Pearson χ2 tests were used to
compare categorical variables, Spearman rank correlation test
was used for nonnormal continuous and ordinal variables, and
the Cochran-Armitage test17,18 was used to test for trend in the
proportions of patients with a given parameter across the in-
come levels. Binomial logistic regression was used to model
the effect of income level (upper-middle–income level and
high-income level combined), presentation age (grouped by
tertiles), familial retinoblastoma history, sex, and bilaterality,
on the likelihood of children having advanced disease (cT4)
at presentation. An α level of .05 and 2-tailed P values were
used to determine statistical significance.
Results
The study sample included 4351 treatment-naive patients
with retinoblastoma residing in 153 countries (Figure). The data
analyzed by national income level are shown in Table 1.
Country-level and continent-level data are shown at http://
globalretinoblastoma.org (password: Ret2017).
Key Points
Question Is the income level of a country of residence associated with
the clinical stage of presentation of patients with retinoblastoma?
Findings In this cross-sectional analysis that included 4351 patients
with newly diagnosed retinoblastoma, approximately half of all new
retinoblastoma cases worldwide in 2017, 49.1% of patients from
low-income countries had extraocular tumor at time of diagnosis
compared with 1.5% of patients from high-income countries.
Meaning The clinical stage of presentation of retinoblastoma,
which has a major influence on survival, significantly differs among
patients from low-income and high-income countries, which may
warrant intervention on national and international levels.
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Geographic and Socioeconomic Characteristics
More than half (2276 [52.3%]) of the patients were from Asia,
1024 (23.5%) were from Africa, 522 (12.0%) were from
Europe, 512 (11.8%) were from the Americas, and 17 (0.4%) were
from Oceania. Of all patients, 533 (12.3%) came from low-
income countries (LICs), 1940 (44.6%) from lower-middle, 1212
(27.9%) from upper-middle, and 666 (15.3%) from HICs.
Completeness of Data
For4116(94.6%)ofthestudypatients,datawerereportedoneach
study parameter, except for age at first ocular symptom of reti-
noblastoma (2175 [50.0%]; not included in the analysis). Analy-
sis by national income level showed that reporting was nearly
complete (≥98.5%) for patients from high-income and upper-
middle–incomecountries,andmorethan94.1%and89.1%forpa-
tientsfromlower-middle–incomecountriesandLICs,respectively.
Symptoms Leading to Referral
The most common first symptom of disease was leukocoria
(n = 2638 [62.8%]), followed by strabismus (n = 429 [10.2%]),
with a further 162 (3.9%) patients having a combination of
leukocoria and strabismus (eTable 3 in the Supplement). Pro-
ptosis was reported in 309 (7.4%) patients. At least 1 symptom
of advanced disease (ie, proptosis, swollen eyelids, red eye) was
reported in 487 (11.7%) patients. A higher income level was as-
sociated with a lower proportion of patients with symptoms of
advanced disease (z score = 10.9, dim = 4; P < .001; additional
analysis is provided in eTable 4 in the Supplement).
Symptoms at Time of Diagnosis at Retinoblastoma Centers
Of all patients, 2998 (70.4%) presented with either leukocoria,
strabismus, or a combination of these symptoms (eTable 3 in
the Supplement). In LICs, combinations of proptosis, red eye,
orbital cellulitis, and extraocular retinoblastoma (ie, advanced
disease) were present in 248 (46.7%) patients. Analysis of
patients who had only leukocoria and/or strabismus (ie, early
disease) as the symptoms noticed by the parents, but who pre-
sented to retinoblastoma treatment centers with symptoms of
advanced disease, showed a significantly larger proportion
coming from LICs (z score = 18.4, dim = 4; P < .001; additional
analysis is provided in eTable 4 in the Supplement).
Age at Diagnosis
The overall median age at diagnosis was 23.5 months (inter-
quartile range [IQR], 11.2-36.5 months; Table 1). The median
age at diagnosis of patients from LICs was 30.5 months (IQR,
18.3-45.9 months) compared with 14.0 months (IQR, 6.2-26.6
months) for patients from HICs. There was a significant asso-
ciation between presentation age and national income level,
with children in LMICs presenting at an older age (eTable 5 in
the Supplement).
Tumor Staging
Globally, the most common cTNM stages were cT3 (n = 1933
of 4114 [47.0%]), N0 (n = 3303 of 4281 [77.2%]), and M0
(n = 3964 of 4275 [92.7%]) (Table 1). Extraocular retinoblas-
toma at time of diagnosis was reported in 926 of 4302 (21.5%)
patients (256 [49.1%] in LICs vs 10 [1.5%] in HICs). Distant me-
tastases were reported in 94 (18.9%), 157 (8.3%), 58 (4.8%), and
2 (0.3%) patients from low, lower-middle, upper-middle, and
high income–level countries, respectively (z score = 11.9,
dim = 4; P < .001). Higher economic grouping was associated
with higher proportions of intraocular and earlier stage dis-
ease at diagnosis (Table 1).
Risk Factors for Advanced Disease at Time of Diagnosis
Sex (χ21 = 1.016; P = .31), bilaterality (χ21 = 0.830; P = .36) and
familial history of retinoblastoma (χ 21 = 2.269; P = .13) were
found to be nonsignificant factors for the prediction of cT4 cat-
egory (extraocular retinoblastoma) and hence were removed
from the model. On logistic regression, low-income level and
older presentation age were found to be independent and sig-
nificant predictive factors for advanced disease (Table 2).
Familial History and Bilateral Retinoblastoma
Familial history of retinoblastoma was reported in 199 of 4215
(4.7%) patients (15 [3.1%], 75 [4.0%], 54 [4.5%], and 55 [8.4%]
patients from low, lower-middle, upper-middle, and high
income–level countries, respectively). Bilateral disease at time
of diagnosis was seen in 1341 of 4351 (30.8%) patients (125
[23.5%], 615 [31.7%], 365 [30.1%], and 236 [35.4%] patients from
low, lower-middle, upper-middle, and high income–level
Figure. Cohort Recruitment Flowchart
298 Retinoblastoma centers from 
134 countries were contacted
Center
recruitment
278 Retinoblastoma centers from 
130 countries joined the study and 
reported 4395 new patients with
retinoblastoma from 153 countriesa
Patient
enrollment
4351 Patients from 153 countries 
were eligible
6 Centers were excluded because they 
had no patients with retinoblastoma 
in 2017
6 Centers were excluded because they
had new patients with retinoblastoma
in 2017 but did not report the patients 
to this study
8 Centers were excluded because they 
had no information available on patients 
with retinoblastoma in 2017
14 Patients were excluded owing to 
duplicate reporting
30 Patients were excluded because they 
did not fulfill the inclusion criteriab
a Patients from 23 countries with no retinoblastoma centers were treated
outside of their country of residence.
b Inclusion criteria included reporting of country of residence, sex, and laterality.
Patients for whom 1 or more of these parameters were not available were not
included in the analytic sample.
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Table 1. Clinical Characteristics at Presentation of 4351 New Patients With Retinoblastoma Diagnosed in 2017
Parameter
National Income Level,
No. (% within the national income level) [% within the evaluated parameter]
Total, No. (%) Significance P ValueLow Lower-Middle Upper-Middle High
Age at diagnosis,
median (IQR), mo
Total sample 30.5 (18.3-45.9) 24.4 (12.2-37.3) 20.7 (10.1-33.8) 14.0 (6.2-26.6) 23.5 (11.2-36.5)
ρ: −0.22 <.001a
Unilateral 35.0 (22.2-48.0) 29.1 (18.1-42.9) 25.5 (12.9-37.6) 19.7 (9.0-32.4) 27.1 (15.0-41.0)
Bilateral 22.9 (11.8-32.8) 14.4 (8.0-25.8) 11.4 (6.0-21.0) 8.1 (3.7-15.8) 12.3 (6.1-24.3)
Reported cases, No. (%) 524/533 (98.3) 1909/1940 (98.4) 1192/1212 (98.3) 664/666 (99.7) 4289/4351 (98.6)
Laterality at diagnosisb
Unilateral 408 (76.5) [13.6] 1325 (68.3) [44.0] 847 (69.9) [28.1] 430 (64.6) [14.3] 3010/4351 (69.2)
NA <.001c
Bilateral 125 (23.5) [9.3] 615 (31.7) [45.9] 365 (30.1) [27.2] 236 (35.4) [17.6] 1341/4351 (30.8)
Familial history
of retinoblastoma
No 467 (96.9) [11.6] 1805 (96.0) [44.9] 1141 (95.5) [28.4] 603 (91.6) [15.0] 4016/4215 (95.3)
z score:
−4.3, dim: 4 <.001
dYes 15 (3.1) [7.5] 75 (4.0) [37.7] 54 (4.5) [27.1] 55 (8.4) [27.6] 199/4215 (4.7)
Total, No. (%) 482/533 (90.4) 1880/1940 (96.9) 1195/1212 (98.6) 658/666 (98.8) 4215/4351 (96.9)
Primary tumor
cT1 5 (1.0) [1.8] 96 (5.1) [35.3] 67 (6.1) [24.6] 104 (15.9) [38.2] 272/4114 (6.7)
z score:
22.3, dim: 4 <.001
e
cT2 62 (12.6) [4.9] 406 (21.7) [31.8] 482 (44.1) [37.8] 326 (49.7) [25.5] 1276/4114 (31.0)
cT3 209 (42.6) [10.8] 1013 (54.1) [52.4] 488 (44.6) [25.2] 223 (34.0) [11.5] 1933/4114 (47.0)
cT4 215 (43.8) [34.0] 359 (19.2) [56.7] 56 (5.1) [8.8] 3 (0.4) [0.4] 633/4114 (15.4)
Total, No. (%) 491/533 (92.1) 1874/1940 (96.6) 1093/1212 (90.2) 656/666 (98.5) 4114/4351 (94.6)
Regional lymph node
NX 105 (20.7) [12.6] 350 (18.4) [42.1] 267 (22.2) [32.1] 109 (16.4) [13.1] 831/4281 (19.4)
z score: 8.3,
dim: 4 <.001
f
N0 360 (71.0) [10.9] 1475 (77.3) [44.7] 912 (75.9) [27.6] 556 (83.6) [16.8] 3303/4281 (77.2)
N1 42 (8.3) [28.6] 82 (4.3) [55.8] 23 (1.9) [15.6] 0 147/4281 (3.4)
Total, No. (%) 507/533 (95.1) 1907/1940 (98.3) 1202/1212 (99.2) 665/666 (99.8) 4281/4352 (98.4)
Distant metastasis
M0 404 (81.1) [10.2] 1749 (91.8) [44.1] 1147 (95.2) [28.9] 664 (99.7) [16.8] 3964/4275 (92.7)
z score:
11.9, dim: 4 <.001
g
cM1 65 (13.1) [30.4] 110 (5.8) [51.4] 39 (3.2) [18.2] 0 214/4275 (5.0)
pM1 29 (5.8) [29.9] 47 (2.5) [48.5] 19 (1.6) [19.6] 2 (0.3) [2.1] 97/4275 (2.3)
Total, No. (%) 498/533 (89.1) 1906/1940 (98.2) 1205/1212 (99.4) 666/666 (100) 4275/4351 (98.3)
Hereditary trait
HX 360 (72.7) [14.2] 1211 (63.8) [47.9] 736 (61.6) [29.1] 221 (33.4) [8.7] 2528/4250 (59.5)
NA NA
H0 0 44 (2.3) [17.3] 59 (4.9) [23.2] 151 (22.8) [59.4] 254/4250 (6.0)
H1 135 (27.3) [9.2] 643 (33.9) [43.8] 400 (33.5) [27.2] 290 (43.8) [19.8] 1468/4250 (34.5)
Total, No. (%) 495/533 (92.9) 1898/1940 (97.8) 1195/1212 (98.6) 662/666 (99.4) 4250/4351 (97.7)
Extraocular
retinoblastoma
No 265 (50.9) [7.8] 1393 (73.0) [41.3] 1062 (88.0) [31.5] 656 (98.5) [19.4] 3376/4302 (78.5)
z score:
21.8, dim: 4 <.001
hYes 256 (49.1) [27.6] 515 (27.0) [55.6] 145 (12.0) [15.7] 10 (1.5) [1.1] 926/4302 (21.5)
Total, No. (%) 521/533 (97.7) 1908/1940 (98.4) 1207/1212 (99.6) 666/666 (100) 4302/4351 (98.9)
International
Retinoblastoma
Staging System
Stage 0 44 (8.7) [3.0] 459 (24.2) [31.3] 585 (48.8) [39.9] 378 (56.8) [25.8] 1466/4264 (34.4)
NA NA
Stage I 170 (33.8) [1.0] 816 (43.0) [47.9] 444 (37.0) [26.1] 272 (40.8) [16.0] 1702/4264 (39.9)
Stage II 58 (11.5) [27.2] 111 (5.9) [52.1] 40 (3.3) [18.8] 4 (0.6) [1.9] 213/4264 (5.0)
Stage III 101 (20.1) [26.1] 242 (12.8) [62.5] 41 (3.4) [10.6] 3 (0.5) [0.7] 387/4264 (9.1)
Stage IV 94 (18.7) [29.9] 157 (8.3) [50.0] 60 (5.0) [19.1] 3 (0.5) [1.0] 314/4264 (7.4)
NA 36 (7.2) [19.8] 111 (5.9) [61.0] 29 (2.4) [15.9] 6 (0.9) [3.3] 182/4264 (4.3)
Total, No. (%) 503/533 (94.4) 1896/1940 (97.7) 1199/1212 (98.9) 666/666 (100) 4264/4351 (98.0)
Abbreviations: IQR, interquartile range; NA, not applicable.
a Spearman rank correlation.
b Inclusion criteria: 100% reporting.
c Fisher exact test for proportion of bilateral cases.
d Cochran-Armitage test for proportion of familial history of retinoblastoma.
e Cochran-Armitage test for proportion of cT3 or greater.
f Cochran-Armitage test for proportion of cases with lymph node involvement.
g Cochran-Armitage test for proportion of cases with distant metastasis.
h Cochran-Armitage test for proportion of cases with extraocular disease.
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countries, respectively) (Table 1). Significantly more familial
(z score = −4.3, dim = 4; P < .001) and, independently, more
bilateral cases were seen in HICs compared with LICs.
Diagnostic Facilities and Treatment Modalities
The available diagnostic and treatment modalities are shown
in eTable 6 in the Supplement. The majority of patients (4201
[96.6%]) were diagnosed in a center that contained resources
for computed tomography and/or magnetic resonance imaging.
A histopathology service was available for 4236 (97.4%) par-
ticipants, and intravenous chemotherapy for 4263 (98.0%).
Global Magnitude of Retinoblastoma
and Representativeness of the Study
Given that the mean age at the time of diagnosis was approxi-
mately 2 years old, the 2015 birth rate data were used for cal-
culation of the number of new retinoblastoma cases.16 Accord-
ing to these data, the predicted annual number of new
retinoblastoma cases worldwide ranged from 7752 to 8914. Using
an average incidence figure of 1 of 17 000 live births, capture
rates were 88.2%, 56.5%, 48.7%, and 39.9% of expected cases
from high, upper-middle, lower-middle, and low-income coun-
tries, respectively. No data were received from 65 countries and
principalities, mainly with small populations; the estimated
number of missing cases from these countries was 46.
Discussion
Findings of this study show a large disparity in the presenta-
tion patterns of retinoblastoma between HICs and LMICs. A
total of 666 children were from HICs, 99% of whom had at the
time of diagnosis a tumor confined to the eye and thus a fa-
vorable prognosis. In comparison, of the 3685 patients from
LMICs, 25% were diagnosed with tumor spread beyond the
globe, for which the prognosis is much worse.19,20 It is likely
that the real gap in the pattern of retinoblastoma presenta-
tion is even wider owing to unreported patients in LICs who
never arrived at a retinoblastoma treatment center and for
whom death from metastatic disease is inevitable.
Late cancer diagnosis, also in the pediatric population, is
a major issue in LMICs.21-25 This study confirms this finding
for retinoblastoma, which, if detected early, can be cured. These
findings are consistent with a recent study of global disease
burden that found that cancer among 0- to 4-year-olds
accounts for 37% of the global disease-adjusted life year; this
proportional burden is greater in LMICs.26
The factors causing delay in retinoblastoma diagnosis and
treatment in LMICs are beyond the scope of this study. However,
the findings here suggest that late recognition of signs of retino-
blastoma, as well as delay in reaching a dedicated retinoblastoma
treatmentcenteronceocularsymptomshavebeendetected,likely
play a role, and both factors are associated with national income
level. These findings indicate clinically significant progression of
signs between parental detection and presentation to a special-
ist center in LMICs. Earlier recognition of leukocoria or strabis-
mus and urgent referral for diagnosis is very important if children
are to receive treatment before extraocular spread occurs.
A familial history of retinoblastoma followed the same pat-
tern, with relatively fewer cases in lower-income countries. A
possible explanation could be underreporting or inadequate
medical record keeping in resource-limited settings. How-
ever, a more plausible explanation would be that children with
familial history of disease are diagnosed and treated early in
HICs so that they survive to childbearing age, whereas this may
not be the case in LMICs.
Nearly all essential diagnostic and therapeutic modali-
ties were available in most participating treatment centers.
Enucleation surgery, which was available in all treatment cen-
ters, can save lives, and intravenous chemotherapy, which was
available for 98.0% of the patients in this study, can save lives
and also result in globe salvage if patients are diagnosed and
treated in time.27,28
The results of this study point to an urgent need to im-
prove retinoblastoma detection and access to treatment in
LMICs. Several initiatives are addressing this challenge by
implementing twinning programs that link centers from higher-
resource and lower-resource countries.12,29-32 However, there
is a pressing need for coordinated action on a global level. In a
rare yet curable cancer such as retinoblastoma, with approxi-
mately 8000 new patients annually worldwide, such an ac-
tion is feasible to make retinoblastoma a zero-death cancer.33
The World Health Organization Global Initiative for Child-
hood Cancer aims to raise survival for key childhood cancers,
including retinoblastoma, to 60% by the year 2030 by help-
ing health systems in LMICs integrate childhood cancer into
their national strategies and improve their capacity to diag-
nose and deliver curative treatment.34 In this context, accu-
rate retinoblastoma-specific data are essential. The results of
this study serve as a report of the current retinoblastoma pre-
sentation status, against which future interventions can be
measured, and demonstrate the need for a strong global part-
nership to improve outcomes for patients with retinoblas-
toma everywhere.
Table 2. Logistic Regression Analysis: Predictors of Advanced Disease at Presentationa,b
Variable B (SE) Corrected P Value Odds Ratio (95% CI)
Income level
Low vs (upper-middle + high) 2.886 (0.166) <.001 17.92 (12.94-24.80)
Low-middle vs (upper-middle + high) 1.748 (0.148) <.001 5.74 (4.30-7.68)
Age at diagnosis
14.27-31.20 mo 1.343 (0.167) <.001 3.83 (2.76-5.31)
>31.20 mo 2.026 (0.160) <.001 7.58 (5.54-10.38)
Constant −4.602 (0.190) <.001 0.01
a The logistic regression model was
statistically significant (χ 24 = 727.27;
P < .001). The model explained
28.5% (Nagelkerke R2) of the
variance and correctly classified
85.1% of cases. Area under the
curve was 0.813.
b Advanced disease is defined as cT4.
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Results of the present study showed that older age at presen-
tation and, independently, national income level were associated
with advanced disease, which suggests that other factors besides
agemaybeimportantindiseaseprogression.Ithasbeensuggested
thatinfectionbythehumanpapillomavirus,whichismorepreva-
lent in LMICs, is associated with the development of nonheredi-
tary retinoblastoma, and it is possible that this could be associ-
ated with more aggressive disease behavior.35 Another possible
explanationrelatestothegeneticlandscapeofretinoblastomaand
especially to cases with no RB1 mutation but a high level of am-
plification of the oncogene MYCN.36 These cases are unilateral,
develop at an early age, and show aggressive features. They were
found only in 1.4% of unilateral retinoblastoma cases, all from
cohorts in HICs,36 but have not been evaluated in patients from
LICs. Notably, in the present study, there were substantially more
unilateral cases in LICs as compared with other income levels, in
keeping with the above-mentioned hypotheses. However, these
speculations, warrant further studies.
Limitations
Thisstudyhasseveral limitations.First, it includedaconvenience
sample and therefore had an inherent potential bias. Neverthe-
less, to our knowledge, it is the largest and most geographically
comprehensive study in the field of retinoblastoma, and we be-
lieve its findings can be generalized. Second, data collection was
mostlyretrospective,withtheexceptionoftreatmentcentersthat
were recruited early in 2017. However, the simplicity of the study
design and quality assurance process enabled the collection of
almostcompletedata,alsofromLMICs.Third,thesocioeconomic
status of individual families was not included as a variable, and
the national income level was used as a surrogate, an approach
that assumes that all families from the same country are of the
same socioeconomic level.
Conclusions
The findings of this cross-sectional global analysis of retino-
blastoma at the time of diagnosis revealed important differ-
ences in presentation among patients from different coun-
tries, depending on their national income level. Patients with
retinoblastoma from HICs present with early disease and are,
therefore, likely to survive. In contrast, patients from lower-
income settings present with late disease, many with extraocu-
lar extension and some already with metastasis, and their prog-
nosis is poorer. A familial history of retinoblastoma is relatively
uncommon in lower-income countries, likely owing to death re-
lated to late-disease presentation before childbearing years. A
surprise finding of this study is that more advanced disease at
presentation in lower-income countries is not entirely ex-
plained by older age. Further research is warranted to investi-
gate what factors other than age play a role in disease progres-
sion in low-income settings. Prompt action at national and
international levels is warranted to improve health education
about retinoblastoma, as well as access to early diagnosis and
treatment in retinoblastoma treatment centers in LMICs.
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